Junmaikang (adalimumab biosimilar)
/ Shanghai Junshi Biosci, Mabwell (Shanghai) Biosci, Binnopharm
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
December 20, 2022
Mabwell Bioscience Partners with Binnopharm Group to Market 9MW0113, 9MW0321 and 9MW0311 in Russia and Eurasian Economic Union Countries
(PRNewswire)
- "Mabwell Bioscience...announced the company has entered into an licensing agreement with the Russian pharmaceutical company Binnopharm Group, for 9MW0113, 9MW0321 and 9MW0311, its Adalimumab and Denosumab biosimilars, under which Binnopharm Group will have exclusive rights to develop, register, manufacture and market the drugs with a status of local product in Russia and Eurasian Economic Union countries."
Licensing / partnership • Immunology • Oncology • Osteoporosis
November 22, 2022
Junshi Biosciences Announces Approval of Supplemental Application for Additional Indications of Adalimumab Injection
(GlobeNewswire)
- "Shanghai Junshi Biosciences Co., Ltd...announced today that the supplemental application for additional indications of adalimumab injection (project code: UBP1211...) for the treatment of Crohn’s disease, uveitis, polyarticular juvenile idiopathic arthritis, plaque psoriasis in children and Crohn’s disease in children has been approved by the National Medical Products Administration ('NMPA')."
Non-US regulatory • Crohn's disease • Idiopathic Arthritis • Immunology • Inflammatory Bowel Disease • Psoriasis • Uveitis
August 17, 2022
Junshi Biosciences Announces Acceptance of Supplemental Application for Additional Indications of Adalimumab Injection
(GlobeNewswire)
- "Shanghai Junshi Biosciences Co., Ltd...announced today that the Company has received an Acceptance Notice issued by the National Medical Products Administration ('NMPA'). The supplemental application for additional indications of the company’s adalimumab injection (project code: UBP1211, trade name: Junmaikang), including the treatment of Crohn’s disease, uveitis, polyarticular juvenile idiopathic arthritis, plaque psoriasis in children and Crohn’s disease in children, has been accepted."
Non-US regulatory • Crohn's disease • Immunology • Inflammatory Bowel Disease
1 to 3
Of
3
Go to page
1